Exelixis (EXEL) : Graticule Asia Macro Advisors added new position in Exelixis during the most recent quarter end. The investment management firm now holds 70,000 shares of Exelixis which is valued at $746,200 , the company said in a statement filed on Aug 15, 2016 with the SEC.Exelixis makes up approximately 0.31% of Graticule Asia Macro Advisors’s portfolio.
Other Hedge Funds, Including , Lpl Financial reduced its stake in EXEL by selling 13,923 shares or 41.42% in the most recent quarter. The Hedge Fund company now holds 19,691 shares of EXEL which is valued at $209,906.Teachers Advisors Inc reduced its stake in EXEL by selling 2,988 shares or 0.81% in the most recent quarter. The Hedge Fund company now holds 366,510 shares of EXEL which is valued at $3,906,997. Exelixis makes up approx 0.01% of Teachers Advisors Inc’s portfolio.Alambic Investment Management reduced its stake in EXEL by selling 43,300 shares or 52.42% in the most recent quarter. The Hedge Fund company now holds 39,300 shares of EXEL which is valued at $418,938. Exelixis makes up approx 0.09% of Alambic Investment Management’s portfolio.
Exelixis closed down -0.16 points or -1.32% at $11.92 with 3,754,800 shares getting traded on Wednesday. Post opening the session at $11.86, the shares hit an intraday low of $11.771 and an intraday high of $12.15 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
On the company’s financial health, Exelixis reported $-0.16 EPS for the quarter, beating the analyst consensus estimate by $ 0.11 according to the earnings call on Aug 3, 2016. Analyst had a consensus of $-0.27. The company had revenue of $36.25 million for the quarter, compared to analysts expectations of $16.37 million. The company’s revenue was up 353.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.22 EPS.
Many Wall Street Analysts have commented on Exelixis. Company shares were Reiterated by Stifel on Aug 4, 2016 to “Buy”, Firm has raised the Price Target to $ 12 from a previous price target of $10 .Company shares were Reiterated by Leerink Partners on Jun 21, 2016 to “Outperform”, Firm has raised the Price Target to $ 10 from a previous price target of $8 .
Exelixis Inc. is a biopharmaceutical company. The Company is engaged in developing small molecule therapies for the treatment of cancer. The Company is focusing on resources development and commercialization of COMETRIQ (cabozantinib) for the treatment of progressive metastatic medullary thyroid cancer (MTC) in the United States. The Company’s other programs include metastatic renal cell carcinoma (mRCC) a phase III trial comparing cabozantinib to everolimus in patients with mRCC who have experienced disease progression following treatment with at least one prior VEGFR TKI; CELESTIAL a phase III trial comparing cabozantinib with placebo in patients with advanced hepatocellular cancer (HCC) who have previously been treated with sorafenib; NSCLC (non-small cell lung cancer); mCRPC (metastatic castration-resistant prostate cancer) and XL888 a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90).